Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Cognitive Enhancement

PE-22-28

Spadin analog

Classification: Spadin-derived peptide; TREK-1 channel blocker

Mechanism: TREK-1 potassium channel inhibition; enhances serotonergic transmission; neurogenesis

Benefits: TREK-1 inhibition; antidepressant effect; neurogenesis

Evidence tier: Preclinical · Availability: Research

Primary sources

  1. Djillani A et al. Fighting against depression with TREK-1 blockers — past and future, focus on spadin. Pharmacol Ther 2019. PMID 30291907
  2. Note: Preclinical evidence only — no published human clinical trials. Cited paper describes in-vitro or animal-model mechanism.

Loading interactive view…